Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZ371B in ARDS
NCT05384379Phase 1Terminated
- Sponsor
- Biozeus
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZ371B in acute respiratory distress syndrome (ARDS), sponsored by Biozeus. Primary endpoints: PaO2/FiO2 Ratio at 4 days, Shunt Ratio at 4 days and 4 more. Started Nov 2022; status: terminated.
02
Drugs
BZ371B
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05384379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384379.